Skyepharma, the maker of drug delivery systems, is close to an agreement to renegotiate its bonds, as it announced a reduction in losses and increased revenues.

Skyepharma makes inhalers as well as tablet formulations that allows a single pill to release different drug compounds at different rates into the body. Its customers include AstraZeneca, Roche, Novartis and GlaxoSmithKline.